Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Exchange Rate Effect: 2015-2025

Historic Exchange Rate Effect for Ptc Therapeutics (PTCT) over the last 11 years, with Sep 2025 value amounting to -$6.1 million.

  • Ptc Therapeutics' Exchange Rate Effect fell 170.99% to -$6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year decrease of 3.53%. This contributed to the annual value of -$7.3 million for FY2024, which is 335.32% down from last year.
  • As of Q3 2025, Ptc Therapeutics' Exchange Rate Effect stood at -$6.1 million, which was down 144.63% from $13.6 million recorded in Q2 2025.
  • Ptc Therapeutics' 5-year Exchange Rate Effect high stood at $13.6 million for Q2 2025, and its period low was -$12.1 million during Q3 2022.
  • For the 3-year period, Ptc Therapeutics' Exchange Rate Effect averaged around $791,182, with its median value being -$2.0 million (2024).
  • As far as peak fluctuations go, Ptc Therapeutics' Exchange Rate Effect slumped by 57,514.29% in 2021, and later spiked by 508.85% in 2023.
  • Ptc Therapeutics' Exchange Rate Effect (Quarterly) stood at -$3.9 million in 2021, then surged by 254.84% to $6.0 million in 2022, then plummeted by 48.59% to $3.1 million in 2023, then plummeted by 379.58% to -$8.7 million in 2024, then plummeted by 170.99% to -$6.1 million in 2025.
  • Its last three reported values are -$6.1 million in Q3 2025, $13.6 million for Q2 2025, and $5.4 million during Q1 2025.